Imago BioSciences, Inc. Financing Cash Flow
Imago BioSciences, Inc. reported Financing Cash Flow of -$4.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2022-11-09
- Imago BioSciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-09-30 was -$475.00K, a 100.29% decline year-over-year.
- Imago BioSciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-06-30 was $17.00K.
- Imago BioSciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-03-31 was $454.00K.
- Imago BioSciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2021-12-31 was $390.00K, a 99.51% decline year-over-year.
- Imago BioSciences, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $160.99M, a 52.47% increase from fiscal 2020.
- Imago BioSciences, Inc. net cash provided by (used in) financing activities for fiscal 2020 was $105.59M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$475.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$458.00K derived: sum of 2 quarters · filed 2022-11-09 | -$4.00K 10-Q · filed 2022-11-09 | $386.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $471.00K 10-Q · filed 2022-08-12 | $861.00K derived: sum of 3 quarters · filed 2022-08-12 | $162.37M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $454.00K 10-Q · filed 2022-05-12 | $844.00K derived: sum of 2 quarters · filed 2022-05-12 | $162.35M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $161.89M derived: sum of 2 quarters · filed 2022-11-09 | $160.99M 10-K · filed 2022-03-24 | |
| 2021-09-30 | $161.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $160.60M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$902.00K 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | $79.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $99.62M derived: sum of 2 quarters · filed 2022-03-24 | $105.59M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $19.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $25.86M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $5.97M 10-Q · filed 2021-08-19 |